Rare Brain Disorder Gets Its First FDA Drug Approval
The first disease-modifying treatment reduced abnormal GFAP production and showed 33% better gait-speed results than control in the pivotal study, Ionis said.
- On Thursday, the U.S. Food and Drug Administration approved Ionis Pharmaceuticals' Zanvastro for Alexander disease, marking the first therapy authorized for this rare and fatal neurological condition affecting fewer than 1,000 people in the U.S.
- Alexander disease is a progressive, fatal condition caused by toxic accumulation of GFAP protein in brain astrocytes, which damages the nervous system over time and typically leads to death within 14 to 25 years after symptom onset.
- In a pivotal clinical study, patients treated with Zanvastro demonstrated stabilized gait speed over 61 weeks, while the control group saw a 33% decline, establishing the drug's efficacy in addressing the underlying disease mechanism.
- The FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher worth $100 million to $200 million alongside approval, and the company expects Zanvastro to reach the U.S. market in the coming weeks.
- In June 2026, Ionis licensed exclusive development and commercialization rights outside the U.S. to Italy-based Recordati, with regulatory submissions in Europe and Japan planned for 2027, positioning the therapy for global reach.
23 Articles
23 Articles
Ionis Pharmaceuticals has obtained regulatory approval in the United States for an unprecedented drug aimed at treating a rare brain disease, but Wall Street is reacting with indifference to the news for a simple reason. Exclusive material for subscribers. To have full access, access the link of the material and make your registration.
Rare Brain Disorder Gets Its First FDA Drug Approval
(MedPage Today) -- The FDA approved zilganersen (Zanvastro) to treat Alexander disease in pediatric and adult patients, the agency announced Thursday. The antisense oligonucleotide, the first approved treatment for Alexander disease, directly...
MarketBeat
thecerbatgem.comIonis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene. The approval includes a bro
Coverage Details
Bias Distribution
- 85% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
